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lower compared with DNMT1 and DNMT3A, both in 
PBMCs from affected patients and those from control sub-
jects. Furthermore, the DNMT1 transcript levels were posi-
tively correlated with SLE disease activity index (SLEDAI) 
(rs  =  0.4087, p = 0.020224), while the DNMT3A tran-
script levels were negatively correlated with patients age 
(rs = −0.3765, p = 0.03369).
Conclusions Our analyses confirmed the importance 
of epigenetic alterations in SLE etiology. Moreover, our 
results suggest that the presence of some clinical mani-
festations, such as phototosensitivity and arthritis, might 
be associated with the dysregulation of DNA methyltrans-
ferases’ mRNA expression levels.
Keywords SLE · Epigenetic alterations · DNA 
methylation
Introduction
Systemic lupus erythematosus (SLE) is a chronic relaps-
ing autoimmune disorder with a spectrum of clinical mani-
festations and outcomes [1]. SLE affects many tissues and 
organs (such as the skin, kidneys, joints, respiratory and 
nervous systems); nevertheless, etiology of this heterogene-
ous disorder remains incompletely described. Currently, it 
is established that SLE is the result of interactions between 
genetic, epigenetic, hormonal, and environmental factors 
[2–6]. SLE, such as many autoimmune diseases, occurs 
more frequently in women, and the reason for this female 
preponderance is suggested role of female sex hormones 
[7]. Recent advances in gene expression analyses, high-
throughput single nucleotide polymorphism (SNP) geno-
typing, and association studies have identified genetic loci 
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Objectives Systemic lupus erythematosus (SLE) is a 
chronic relapsing autoimmune disease characterized by the 
presence of autoantibodies directed against nuclear anti-
gens and by chronic inflammation. Although the etiology of 
SLE remains unclear, the influence of environment factors, 
which is largely reflected by the epigenetic mechanisms, 
with DNA methylation changes in particular, is generally 
considered as main players in the pathogenesis of SLE. We 
studied DNA methyltransferases’ (DNMTs) type 1, 3A and 
3B transcript levels in peripheral blood mononuclear cells 
from patients diagnosed with systemic lupus erythemato-
sus and from the healthy control subjects. Furthermore, the 
association of DNMT1, DNMT3A, and DNMT3B mRNA 
levels with gender, age, and major clinical manifestations 
was analyzed.
Methods Peripheral blood mononuclear cells (PBMCs) 
were isolated from 32 SLE patients and 40 healthy controls. 
Reverse transcription and real-time quantitative polymerase 
chain reaction (RT-qPCR) analyses were used to determine 
DNMT1, DNMT3A, and DNMT3B mRNA expression 
levels.
Results Significantly lower DNMT1 (p = 0.015543) and 
DNMT3A (p = 0.003652) transcript levels in SLE patients 
were observed compared with healthy controls. Neverthe-
less, the DNMT3B mRNA expression levels were markedly 
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or genes that dictate immune abnormalities in autoimmune 
diseases [8, 9].
Nevertheless, multiple studies have demonstrated a 
pivotal role of epigenetic mechanisms of gene regula-
tion in SLE etiology. In contrast to genetic alterations, an 
epigenetic change is defined as a heritable change in gene 
expression that does not involve a change in the DNA 
sequence [10]. Epigenetic mechanisms play an essential 
role in eukaryotic gene regulation by modifying chromatin 
structure, which in turn modulates gene expression. There 
are three processes that have been most frequently impli-
cated in epigenetic control: histone modification, DNA 
methylation, and microRNA expression patterns [6]. Meth-
ylation of deoxycytosine (dC) bases in CG pairs, referred 
to as DNA methylation, is the most common epigenetic 
mechanisms of gene regulation. CG pairs are found ubiqui-
tously throughout the genome. Among all the CpGs in the 
human genome, 6080% are generally methylated. Less than 
10% of CpGs occur in CG-dense regions that are termed 
CpG islands [11]. However, their transcriptionally repres-
sive activity is generally ascribed to promoter regions [12]. 
DNA methylation contributes to systemic lupus erythe-
matosus predisposition and is generally considered as key 
player in the pathogenesis of SLE [13]. Twin studies con-
firmed the importance of DNA demethylation in human 
lupus [14].
The addition of a methyl group to the fifth position 
of the cytosine pyrimidine ring, predominantly at CpG 
dinucleotides, is mediated by DNA methyltransferases 
(DNMTs). De novo methylation and maintenance meth-
ylation are two distinct processes that are required for the 
establishment and mitotic inheritance of tissue-specific 
methylation patterns (Fig. 1). Among group of the DNMTs, 
DNMT3A and DNMT3B catalyze de novo DNA methyla-
tion, and DNMT1 mediates the maintenance of DNA meth-
ylation [11]. DNMT1 is the maintenance DNA methylation 
enzyme, recognizing hemimethylated cytosines during the 
S phase of the cell cycle and copying these marks onto 
the nascent strand during replication [15, 16]. Studies 
with the embryonic stem cells (ES cells) with inactivated 
DNMT3A and DNMT3B genes by gene targeting, dem-
onstrated blocks de novo methylation in ES cells and early 
embryos [17]. These results indicate that both DNMT3A 
and DNMT3B are required for genome-wide de novo meth-
ylation and are essential for mammalian development.
We studied DNMT1, DNMT3A, and DNMT3B tran-
script levels in peripheral blood mononuclear cells 
(PBMCs) from 32 patients diagnosed with SLE and from 
40 individuals as a control group.
Materials and methods
Human subjects
Thirty-two peripheral blood samples were obtained from 
patients diagnosed with SLE at the Department of Rheuma-
tology and Internal Diseases in Poznan, Poland (Table 1), 
and 40 samples from the control group (40 females; median 
age = 30, range 19–47, mean age ± SD = 30.8 ± 8.6) were 
collected at the Regional Blood Donation and Blood 
Treatment Center in Poznan, Poland. The healthy control 
Fig. 1  Maintenance (a) and 
de novo DNMTs (b) methylate 
DNA. DNMT1 binds methyl 
groups to the hemimethyl-
ated DNA during replica-
tion, whereas DNMT3A and 
DNMT3B can add methyl 
groups to CpG dinucleotides 
of unmethylated DNA. From 
Luczak and Jagodziński [23]
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subjects were selected from healthy blood donors without 
any rheumatologic conditions. At the time of blood dona-
tion, the median and mean age of the patients were 36 
(range 19–74) and 37.9 ± 14.4  years, respectively. Based 
on the SLE disease activity index (SLEDAI), SLE patients 
were divided into 12 inactive (SLEDAI <6) and 20 active 
(SLEDAI ≥6) cases. Peripheral blood samples were col-
lected from all the patients before they took any immu-
nosuppressive drug, glucocorticoid or cytotoxic drugs to 
exclude the influence of drugs. The study procedures were 
approved by the Local Ethical Committee of Poznań Uni-
versity of Medical Sciences.
Isolation of PBMCs
Human peripheral blood mononuclear cells were iso-
lated using Ficoll density gradient centrifugation method. 
Ficoll is a neutral, high-mass, branched polysaccharide 
that simply dissolves in aqueous solutions [18]. Blood 
(3  mL) was gently layered on top of an equal volume of 
Ficoll® (Sigma) solution (without mixing the two layers) 
in a 15 mL conical tube. The samples were centrifuged at 
600×g for 50 min at room temperature whit the brake in the 
off position. PBMCs are retained at the interface between 
the Ficoll and plasma layers. The layer containing the 
mononuclear cells was harvested in 1.5  mL microcentri-
fuge tubes. In the next step, cells were washed in phosphate 
buffered saline (PBS) supplemented with 2  mM EDTA. 
Finally, after centrifugation at 250×g for 10 min, cells were 
resuspended in TRIzol® Reagent (Invitrogen, USA) for 
downstream applications.
Reverse transcription and real‑time quantitative 
polymerase chain reaction (RT‑qPCR) analyses
Total RNA from PBMCs was isolated according to the 
method published by Chomczyński and Sacchi [19]. RNA 
integrity was determined by denaturing agarose gel elec-
trophoresis, and then, the RNA was quantified by measur-
ing the optical density (OD) at 260 nm. RNA samples were 
treated with DNase I and reverse-transcribed into cDNA 
using Moloney Murine Leukemia Virus (M-MLV) Reverse 
Transcriptase from Invitrogen, Life Technologies (Grand 
Island, NY), according to the manufacturer’s protocol. RT-
qPCR was conducted in a Light Cycler®480 Real-Time 
PCR System, Roche Diagnostics GmbH (Mannheim, Ger-
many) with SYBR Green I as the detection dye. The target 
cDNA was quantified by the relative quantification method 
using a calibrator for patient or control PBMCs. For the 
calibrator, 1  μl of cDNA from all samples were mixed 
together, and successive dilutions were used to create a 
standard curve as described in the Relative Quantification 
Manual Roche Diagnostics GmbH (Mannheim, Germany). 
For relative quantification, we applied the E-Method algo-
rithm. The DNMT1, DNMT3A, and DNMT3B transcript 
levels in each sample were standardized to the porpho-
bilinogen deaminase (PBGD) transcript level as an internal 
control. The DNMT1, DNMT3A, and DNMT3B transcript 
levels in PBMCs from the patients with SLE and the con-
trols were expressed as a multiplicity of the cDNA con-
centration in the calibrator. For the amplification reactions, 
1 μL of total (20 μl) cDNA solution was added to 9 μL of 
5× LightCycler® 480 SYBR Green I Master from Roche 
Diagnostics GmbH (Mannheim, Germany) with primers 
(Table 2). Agarose gel electrophoresis was applied to con-
firm the specificity of the amplified products.
Statistical analysis
The normality of the observed patient data distribution 
was assessed by the Shapiro–Wilk test, followed by the 
Mann–Whitney U test to identify statistically significant 
differences between the compared mean values. Correla-
tions were calculated using Spearman’s rank correlation 
coefficient (rs). p values <0.05 were considered to be sta-
tistically significant. Statistical analyses were performed 
using the STATISTICA 12 software.
Table 1  Demographic and clinical characteristics of SLE patients
Parameter SLE patients (n = 32)
Demographic data Mean ± SD
 Age (years) 37.9 ± 14.4
 Disease duration (years) 9.9 ± 7.9
 Gender (female/male) 30/2
 SLEDAI 7.7 ± 6.1
Clinical manifestations No (%)
 Malar rash 10 (31.3)
 Discoid rash 11 (34.4)
 Phototosensitivity 18 (56.3)
 Oral ulcers 14 (43.8)
 Arthritis 9 (28.1)
 Serositis 4 (12.5)
 Renal disorders 16 (50)
 Neurological disorders 12 (37.5)
 Haematological disease 7 (21.9)
 Immunological disorders 18 (56.3)
 Anti-nuclear Ab 32 (100)
 Anti-dsDNA Ab 13 (40.6)
 Anti-Smith Ab 7 (21.9)
 Anti-snRNP Ab 7 (21.9)
 Anti-Ro Ab 4 (12.5)
 Anti-La Ab 6 (18.8)




In the present study, employing RT-qPCR to compare the 
mRNA levels, DNMT1, DNMT3A, and DNMT3B tran-
scripts in peripheral blood mononuclear cells from patients 
with SLE and healthy individuals were identified. Never-
theless, the DNMT3B transcript levels were markedly lower 
compared with DNMT1 and DNMT3A, both in PBMCs 
from affected patients (p < 0.00001 for DNMT1 and 
DNMT3A) and those from control subjects (p < 0.00001 
for both enzymes also; Fig. 2). Significantly lower DNMT1 
transcript expression (p = 0.015543) was observed in the 32 
SLE patients than in the healthy controls. DNMT3A tran-
script levels also decreased significantly (p = 0.003652) in 
patients diagnosed with SLE compared with the controls. 
SLE patients and controls showed similar mRNA levels of 
DNMT3B (p = 0.852599).
We also analyzed the relationships between DNMT1, 
DNMT3A, and DNMT3B mRNA expression levels and 
gender, age, and major clinical manifestations (listed in 
Table  1). Regarding the correlation of mRNA expres-
sion levels among SLE patients, DNMT1 transcript levels 
were positively correlated with SLE disease activity index 
(SLEDAI) (rs  =  0.4087, p = 0.020224; Fig.  3a). Interest-
ingly, DNMT1 mRNA levels in active (SLEDAI ≥6) SLE 
patients were slightly higher compared with inactive (SLE-
DAI <6) SLE group; nevertheless, it was not statistically 
significant (p = 0.054007). Furthermore, the DNMT3A 
transcript levels were negatively correlated with patients 
age (rs = −0.3765, p = 0.03369; Fig. 3b). This result sug-
gests a lower mRNA expression levels of DNMT3A in 
older group of SLE patients (age >40); however, there 
was no statistically significant difference in the expres-
sion of DNMT3A mRNA among the different age groups 
(p = 0.076547). Substantial increase of DNMT3A mRNA 
amount in PBMCs (p = 0.023808) was observed in the 
group of patients with phototosensitivity (18 patients, 
56.3%; Fig. 4a). Furthermore, individuals with arthritis (9 
patients, 28.1%) were found to have significantly lower lev-
els of DNMT3B mRNA levels (p = 0.029297) than patients 
without arthritis (Fig. 4b).
Discussion
Genetic and epigenetic alterations unquestionably play a 
pivotal role in etiology of systemic lupus erythematosus 
(SLE). Studies of epigenetic aberrations in lupus patients 
have primarily focused on DNA methylation and various 
covalent histone modifications. DNA methylation is an epi-
genetic mark that is critical in determining chromatin acces-
sibility and regulating gene expression. This epigenetic 
mechanism most frequently occurs at the fifth carbon of the 
pyrimidine ring in cytosine residues, primarily located in 
cytosine–guanosine dinucleotides (CpG dinucleotides). To 
this day have been described different patterns by which 
this epigenetic modification may affect chromatin accessi-
bility. DNA methylation in the promoter regions is associ-
ated with gene silencing, thus linking DNA methylation to 
chromatin inaccessibility and gene suppression [20]. Inter-
estingly, Hughes et al. [12] demonstrated that DNA meth-
ylation in gene promoter regions is not always a repressive 
epigenetic mark. Nevertheless, recent studies have also 
focused on the roles of DNA methylation in gene bodies 
and intergenic regions in enhancing gene expression [21, 
22]. The mammalian DNA cytosine-5-methyltransferases’ 
(DNMTs) family comprises DNMT1, DNMT2, DNMT3A, 
DNMT3B, and DNMT3L; however, DNMT3L is primarily 
Table 2  Primer sequences
Gene Sequence (5′–3′) Product 
size 
(bp)
DNMT1 F: GAT GAG AAG AAG CAC AGA AGT
R: TCT TTG GGG GTC GTT TTG CG
149
DNMT3A F: GGT GCT GTC TCT CTT TGA TG
R: ATG CTT CTG TGT GAC GCT G
178
DNMT3B F: GGA AGG AGT TTG GAA TAG GG
R: CCA GTG CCA CCA GTT TGT C
183
PBGD F: GCC AAG GAC CAG GAC ATC 
R: TCA GGT ACA GTT GCC CAT C
160
Fig. 2  DNMT1, DNMT3A, and DNMT3B transcript levels in 
peripheral blood mononuclear cells (PBMCs) from patients with 
diagnosed SLE and control group. PBMCs from SLE patients (n = 32, 
filled circles) and controls (n = 40, open circles) were used for RNA 
isolation. Total RNA was reverse-transcribed, and cDNAs were inves-
tigated by RT-qPCR relative quantification analysis. The DNMT1, 
DNMT3A, and DNMT3B mRNA levels were corrected by PBGD 
level. The amounts of DNMT1, DNMT3A, and DNMT3B mRNA 
were expressed as the decimal logarithm of multiples of these cDNA 
copies in the calibrator
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restricted to early embryogenesis, and does not play a 
major role [11, 16]. DNA methylation is established by 
the combined action of three DNMTs (DNMT2 functions 
to methylate RNA): DNMT1 is the maintenance methyl-
transferase and binds methyl groups to the hemimethylated 
DNA during replication, whereas DNMT3A and DNMT3B 
exhibit de novo methyltransferases’ activity and add methyl 
groups to CpG dinucleotides of unmethylated DNA to cre-
ate new patterns of methylation [23, 24]. Thus, we analyzed 
the changes in transcript levels of DNMT1, DNMT3A, and 
DNMT3B in the whole PBMC population.
DNA methylation changes are closely related to the 
pathogenesis of SLE. Many studies have shown that abnor-
mal DNA hypomethylation in some genes of CD4+ T 
cells can result in creation of autoreactive T cells and 
autoantibody generation. The most important methylation-
sensitive T-cell genes include inter alia CD11a (encoded 
by gene ITGAL), perforin 1 (PRF1), CD70 (TNFSF7), 
CD40 ligand (TNFSF5), or killer-cell immunoglobulin-
like receptors (KIR2DL4) [15, 24–27]. Other studies indi-
cated that demethylation of inflammatory cytokine genes 
from interleukin family in CD4+ T cells might participate 
in the progression of SLE [28]. DNA methylation changes 
in regulatory regions of mentioned genes may be the result 
of action various factors, such as regulatory factor X 1 
(RFX1) [29], overexpression of some microRNA [30–32], 
or long non-coding RNAs (lncRNAs) [33], which through 
interacting with DNMTs affects DNA methylation at distal 
target promoters. Other research found that Ras–mitogen-
activated protein kinase (MAPK) and extracellular receptor 
Fig. 3  a Positive correlation between DNMT1 expression levels in PBMCs and SLEDAI in SLE patients (n = 32). b Negative correlation 
DNMT3A expression levels in PBMCs and SLE patients age (n = 32)
Fig. 4  a DNMT3A mRNA levels in SLE patients with (n = 18, filled circles) and without (n = 14, open circles) photosensitivity. b DNMT3B 
mRNA levels in SLE patients with (n = 9, filled circles) and without (n = 23, open circles) arthritis
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associated kinase (ERK) pathway were involved in DNA 
hypomethylation by down-regulating DNMT activity in 
SLE [34, 35]. To confirm the importance of DNA hypo-
methylation in the progression of SLE, in recent years, 
few laboratories performed high-throughput genome-scale 
DNA methylation analysis and confirmed that the methyla-
tion level of many genes contributed to the development 
of diversified manifestations in SLE [14, 36–38]. Further-
more, by genome-scale DNA methylation analysis, Chung 
et  al. found hypomethylation of CpG sites within genes 
from different pathways, which were involved in the pro-
duction of autoantibodies to nuclear antigens in SLE [39].
In our study, using RT-qPCR analysis, we found 
decreased expression of DNMT1 and DNMT3A mRNA 
levels in SLE patients compared with the healthy individu-
als. As a consequence, and based on our results, we made 
the assumption that PBMCs from patients with SLE may 
be characterized by a global DNA hypomethylation. Other 
investigators demonstrated that both entire pool of PBMCs 
[40] and isolated T cells [41–43] from patients with SLE 
had a global DNA hypomethylation. Balada et al. [42] also 
demonstrated that CD4+ T cells from SLE patients had a 
low DNA methylcytosine content. Nevertheless, in contrast 
to our results, authors have shown similar mRNA levels of 
DNMT1, DNMT3A, and DMT3B in patients and control 
groups. It should be pointed out clearly that these authors 
used only purified CD4+ T cells from the entire pool of 
mononuclear cells. Overall, all enzymes reflected a wide 
range of variability among individuals, especially DNMT1 
and DNMT3A. However, authors in other studies found 
that T cells [35] or PBMCs [44] from patients with lupus 
have exhibited a reduced DNMT1 mRNA levels. Some 
authors suggest that a defect in DNMT1 may be the pri-
mary reason of abnormal DNA methylation in CD4+ T 
cells from lupus patients [25]. Completely different results 
were achieved by Liu laboratory, and authors demonstrated 
significantly increased DNMT1 mRNA expression in SLE 
patients compared with the controls [40]. Other investiga-
tors [43, 45] described significantly higher mRNA levels 
of other enzymes (MBD1, MBD3, and MBD4), involved 
in the DNA methylation process, in patients with lupus. 
Therefore, these investigations suggest that the global DNA 
methylation may be dependent on multiple factors, such as 
DNMT mRNA levels, DNMT activity, DNMT protein lev-
els, and transcript levels of other enzymes involved in the 
DNA methylation process. Nevertheless, our results con-
firmed the importance of epigenetic alterations in SLE eti-
ology. Decreased expression of the DNMT1 and DNMT3A 
might be associated with generation of autoreactive T cells 
and autoantibody production. According to our results, in 
Balada studies [42], authors observed higher transcript 
levels of DNMT1 (moreover also for the DNMT3A) in 
active SLE patients. In the present study, we demonstrated 
markedly lower transcript levels of DNMT3B in PBMCs 
from SLE patients and those from control group—other 
studies also confirmed these observations [32, 42]. These 
results suggest that DNMT3B seems to be transcribed at 
low levels in PBMCs. Therefore, we may postulate that 
DNMT3A is the main enzyme which exhibits de novo 
methyltransferases’ activity in PBMCs both from affected 
patients and those from control subjects to create new pat-
terns of methylation. Subsequent studies of Balada labo-
ratory [27] also demonstrated that SLE patients had sig-
nificantly less CD4+ T-cell DNA deoxymethylocytosine 
content than controls. As shown in this manuscript, ITGAL 
and PRF1 mRNA levels were directly and strongly corre-
lated with the transcript levels of three DNMTs playing the 
lead role in DNA methylation.
In the present study, we also found positive correlation 
between DNMT1 transcript levels and SLE disease activity 
index (SLEDAI). Interestingly, our results suggest slightly 
higher mRNA levels of DNMT1 in group of patients with 
active (SLEDAI ≥6) SLE. The emerging discrepancy may 
be associated, as suggested by some [44] investigators, with 
corticosteroid treatment. Ogasawara et  al. have reported 
that the levels of DNMT1 mRNA by peripheral blood 
mononuclear cells from patients with SLE were increased 
after corticosteroid treatment [44]. Moreover, previously 
published data support the hypothesis that cells respond 
to pharmacological or dietetical inhibition of methylation 
by induction of methyltransferase activity [46, 47]. Some 
authors [48] suggested that the DNMT activity is itself 
regulated, in part, by DNA methylation status, which rep-
resents a feedback mechanism. Investigators have found a 
regulatory region in murine dnmt1 that seems to act as a 
sensor of the DNA methylation capacity of the cell. Fur-
thermore, we observed an inverse correlation between 
the DNMT3A transcript levels and patients age. Whereas 
Zhang et al. [49] also found that the levels of DNMT1 and 
DNMT3A decreased with aging and that this change cor-
related with the hypomethylation of sequences flanking the 
ITGAL promoter. Other studies have shown that in DNA 
from aged subjects (65–90  years) compared with young 
subjects (20–35  years) is significantly decreased global 
level of methylation suggesting that age-associated hypo-
methylation of the DNA may be the cause of its increased 
immunogenicity. This change may thus be another mecha-
nism that may contribute to the increase in age-associated 
chronic inflammation and autoimmunity. Moreover, deliv-
ery of DNA from aged compared with young subjects into 
PBMCs stimulated a significantly greater secretion of an 
inflammatory cytokine (IFN-α) and costimulatory markers 
CD80 and CD86 [50]. Therefore, we may postulate that a 
decrease of DNMTs expression during adulthood may be 
the pathway to development of autoimmunity with aging. 
Our results suggest also that the presence of some clinical 
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manifestations, such as phototosensitivity and arthritis, 
might be associated with the dysregulation of DNA meth-
yltransferases mRNA expression levels. As reviewed 
by Medlin et  al. [51] in pooled analysis of SLE patients, 
most cutaneous manifestations (including phototosensi-
tivity) were less prevalent in the late-onset SLE patients. 
Studies with Xeroderma pigmentosum (genetic disease 
characterized by hypersensitivity to UV exposure, associ-
ated with numerous skin abnormalities) skin cells indicate 
enormous importance of CpG methylation on frequency of 
targeted mutagenesis (TM) [52]. The distribution of TM 
events within the amplicon population was strongly biased 
toward demethylated sequences. Increase of TM frequency 
was observed when the DNMT1 gene was knocked down 
using specific siRNA. In addition, no induction of tar-
geted mutagenesis after 5-aza-dC treatment was observed 
in the cells. Obtained by us results indicate slightly higher 
DNMT3A transcript levels, which may be associated with 
cells respond to pharmacological or dietetical inhibition of 
DNMTs activity. Less significance seems to have changes 
in the DNMT3B mRNA level changes associated with 
arthritis, because according to our results, this enzyme 
plays only a supporting role in methylation in PBMCs.
In our study, we analyzed the changes in transcript lev-
els of DNMT1, DNMT3A, and DNMT3B in the whole 
PBMCs population. Note, mRNA levels in each group of 
immune cells may differ from the overall results obtained 
for PBMCs. For example, our results better reflect epige-
netic changes in CD4 T cells (represent range of 25–60% of 
PBMC) than in B cells (up to 15% of PBMC). In humans, 
the frequencies of these populations vary across individu-
als, and also cell composition might be different in healthy 
controls and patients. The main limitation of our study is 
the lack of correlation between protein and mRNA levels. 
Keeping in mind the small amount of samples, we decided 
to investigate only DNMT1, DNMT3A, and DNMT3B 
mRNA levels.
Conclusion
Our analyses confirmed the importance of epigenetic 
alterations in SLE etiology. Decreased expression of the 
two DNA cytosine-5-methyltransferases (DNMT1 and 
DNMT3A) might be associated with generation of auto-
reactive T cells and autoantibody production. We have 
shown that DNMT3A is the main enzyme which exhibits 
de novo methyltransferases activity in PBMCs both from 
affected patients and those from control subjects. In addi-
tion, our result can indicate the way by which it is achieved 
DNA hypomethylation in some specific genes in SLE 
pathogenesis.
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